HCP 1405Alternative Names: HCP1405
Latest Information Update: 07 Sep 2016
At a glance
- Originator Hanmi Pharmaceutical
- Class Osteoporosis therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Osteoporosis
Most Recent Events
- 19 Aug 2016 Phase-III clinical trials in Osteoporosis (unspecified route)